Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Date:11/16/2011

ent and Chief Executive Officer of Sonus Pharmaceuticals Inc., a publicly traded cancer therapeutics company.  During his tenure, he refocused the company on oncology drug development, and oversaw development of the company's lead cancer therapeutic through a pivotal Phase 3 trial conducted under a special protocol assessment.  In addition, he played an integral role in establishing and managing collaborations with partners, raising capital from public markets and ultimately completing a reverse merger with Oncogenex Pharmaceuticals Inc.  

In 2009, Martino joined with the cofounders of Arzeda Corp., a privately held company focused on enzyme design and development using technology licensed from the University of Washington.  During his tenure as the company's first CEO, he oversaw the company's start-up and fundraising activities, both through private investment and collaborations. In 2010, Martino joined CareFusion Corporation and held multiple positions including Senior Vice President and General Manager of diagnostics and Senior Vice President of Innovation, Business Development and Strategy.  Earlier in his career, he held multiple positions during a 17-year tenure at Mallinckrodt in strategic planning, business development, marketing, and general management, where he completed multiple acquisitions and licensing agreements and led a major restructuring of the company.

Martino received an M.B.A. from Virginia Tech and a bachelor's degree from Roanoke College. He currently serves on the Board of Directors of Arzeda Corp.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as mono-therapy treatment for adult and elderly patients with r
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in ... the PandaPLUS 2000, which is ideal for new applications ... cell disruption . This compact laboratory homogenizer is the ... food, food additives and ingredients as well as for ...
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... YORK, May 2 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) ... Financial Officer., Pulmo BioTech Chief Executive Officer Garry McCann ... join the company and that Rajiv,s,experience and financial acumen would ... completion of its Phase I Human Trials and then into ...
... -- Quarterly Revenues Increase 62% to $11.7 million, ... million with EPS of $0.11, NEW YORK ... Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: ... products in China, today announced its financial results,for ...
... 7, 2008 at 10:00 AM EDT, CEDAR KNOLLS, ... ) will host a conference call discussing,its financial results ... May 7, 2008 at 10:00 AM EDT., A ... through the,company,s website at: http://www.emisphere.com . The live ...
Cached Biology Technology:Pulmo BioTech Announces Appointment of Chief Financial Officer 2Pulmo BioTech Announces Appointment of Chief Financial Officer 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 4China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 5China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 6China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 7China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 8China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 9Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... AGAWAM, Mass., May 13 Microtest Laboratories ... is adding dissolution testing to its current suite of ... services."The addition of dissolution testing ... said Steven Richter, Ph.D., President and Scientific Founder of Microtest ...
... May 20 Validus Technologies Corporation and HierStar ... formed a strategic manufacturing, marketing and distribution alliance ... Time Password (OTP) authentication products to combat cybercrime ... increasing data breaches, which have created a global ...
... scientists have identified two new genes and two new enzymes ... the plants were making monoterpenes, compounds that help give tomato ... the face of accepted thought. Such research could help ... Based on years of research, scientists thought that plants always ...
Cached Biology News:Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 2Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 3Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 2Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 3MSU discoveries upend traditional thinking about how plants make certain compounds 2
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: